Xtalks 网络研讨会：细胞与基因治疗开发中如何用好 FDA 会议

In this free webinar, learn how cell and gene therapy (CGT) sponsors can use FDA meetings to guide development from early planning through marketing application readiness. The featured speakers will discuss INTERACT, pre-IND, Type D and pre-BLA meetings, including when to use them and how to prepare effective briefing packages and questions. Attendees will also explore how to respond to FDA feedback and adjust development plans when a meeting does not go as expected.

, /PRNewswire/ -- Cell and Gene Therapies (CGTs) present unique development challenges, from novel manufacturing processes and delivery methods to complex nonclinical programs and evolving regulatory expectations. For sponsors developing these therapies, engaging with the FDA early and often can help clarify development requirements, identify potential issues, and inform a more efficient path toward the clinic and commercialization. Two questions anchor every FDA interaction along that path: what the therapy is ultimately meant to become and how the evidence to support that goal will be generated. Each FDA meeting is an opportunity to refine both.

In this webinar, multi-disciplinary experts will explore the FDA meeting options available to sponsors throughout development, including INTERACT, Pre-IND, Type D, and Pre-BLA meetings, and their distinct purpose: an INTERACT meeting pressure-tests the product concept before costly IND-enabling work begins, the Pre-IND meeting turns that concept into an executable clinical program, a Type D meeting resolves a discrete issue before it becomes a program-level problem, and the Pre-BLA meeting assesses whether the development package is ready to become a marketing application. The discussion will cover when each meeting may be appropriate, how to request a meeting, and strategies for preparing focused briefing packages and effective questions. And when the conversation doesn't go as planned? The experts will share how sponsors can respond to an unsatisfactory Pre-IND meeting and use the experience to inform next steps.

Understanding how and when to engage with the FDA can help sponsors make better development decisions, reduce avoidable delays, and move their CGT programs forward with greater clarity and confidence.

Register for this webinar to learn how to prepare for productive FDA meetings and respond effectively to regulatory feedback throughout cell and gene therapy development.

Join experts from Premier Research, Greg Meyer, Vice President, Regulatory Affairs; and Ken Ndugga-Kabuye, MD, FACMG, Vice President, Cell & Gene Therapy, for the live webinar on Thursday, November 12, 2026, at 11am EST (5pm CET / EU-Central).

For more information, or to register for this event, visit FDA Meetings: Engaging Regulators Throughout Cell and Gene Therapy Development.

ABOUT XTALKS

Xtalks – The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and research with the trusted knowledge and collaborative insights that move the industry forward. Powered by Honeycomb Worldwide Inc., Xtalks delivers news, feature articles, webinars, podcasts, videos, expert interviews, curated job opportunities and more designed to support informed decision-making in a fast-evolving sector.

Every year, thousands of professionals rely on Xtalks for timely intelligence, peer perspectives and industry thought leadership. Join our life science community to stay informed, connected and ready for what's next.

To learn more about Xtalks, visit www.xtalks.com
For information about working with Xtalks to host your webinar, visit https://xtalks.com/partner-with-us/

Contact:
Soumya Shashikumar
Tel: +1 (416) 977-6555 x371
Email: [email protected]

SOURCE Xtalks